Siddhartha Mukherjee, AP Images

Sid Mukher­jee's Vor adds clin­i­cal man­u­fac­tur­ing fa­cil­i­ty at ex­ist­ing Boston-area site, beef­ing up for a com­mer­cial push

When Sid­dhartha Mukher­jee found­ed Vor Bio­phar­ma in 2016, he had the goal of rewrit­ing the book on stem cell trans­plants. To get there, Vor need­ed a leg up in clin­i­cal man­u­fac­tur­ing — and now it has one.

Vor will build an in-house clin­i­cal man­u­fac­tur­ing fa­cil­i­ty next to its Cam­bridge, MA head­quar­ters, which is an­tic­i­pat­ed to be up and run­ning in 2022, the com­pa­ny said Thurs­day. The out­lay is all out of pock­et, but Vor says the build­out won’t im­pact its cash run­way, which is suf­fi­cient to ear­ly 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.